Randomized placebo-controlled evaluation of hydrazine sulfate in patients with advanced colorectal cancer

Charles L. Loprinzi, Steven A. Kuross, Judith R. O'Fallon, Dean H. Gesme, James B. Gerstner, Raylene M. Rospond, Charles D. Cobau, Richard M. Goldberg

Research output: Contribution to journalArticlepeer-review

79 Scopus citations

Abstract

Purpose: Hydrazine sulfate is a controversial agent that was originally studied in cancer patients approximately 20 years ago. Based on a series of recent trials that suggested that this drug might have utility in cancer patients, we conducted this study. Patients and Methods: Patients with metastatic colorectal cancer were randomized to receive hydrazine sulfate or placebo in a double-blinded manner. Protocol patients did not concurrently receive any other systemic antineoplastic treatment. Results: There were 127 assessable patients entered onto this clinical trial. Data from the study showed trends both for poorer survival and for poorer quality of life (QL) in the hydrazine group. There were no significant differences in the two study arms with regard to anorexia or weight loss. Conclusion: This trial failed to demonstrate any benefit for hydrazine sulfate.

Original languageEnglish (US)
Pages (from-to)1121-1125
Number of pages5
JournalJournal of Clinical Oncology
Volume12
Issue number6
DOIs
StatePublished - Jun 1994

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Randomized placebo-controlled evaluation of hydrazine sulfate in patients with advanced colorectal cancer'. Together they form a unique fingerprint.

Cite this